Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification ma… Read more
Jafron Biomedical Co Ltd (300529) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.010x
Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) has a cash flow conversion efficiency ratio of 0.010x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥35.34 Million) by net assets (CN¥3.43 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jafron Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Jafron Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jafron Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jafron Biomedical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VIZIO HLDG.CL.A DL-0001
F:7UF
|
N/A |
|
Vir Biotechnology Inc
NASDAQ:VIR
|
-0.034x |
|
TripAdvisor Inc
NASDAQ:TRIP
|
-0.160x |
|
Trigano S.A
OTCGREY:TGNOF
|
0.043x |
|
Allied Properties Real Estate Investment Trust
PINK:APYRF
|
0.029x |
|
PT VKTR Teknologi Mobilitas
JK:VKTR
|
-0.020x |
|
Pacific Basin Shipping Limited
PINK:PCFBF
|
0.068x |
|
Nyfosa AB
LSE:0A0K
|
0.018x |
Annual Cash Flow Conversion Efficiency for Jafron Biomedical Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Jafron Biomedical Co Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.33 Billion | CN¥1.05 Billion | 0.315x | +8.39% |
| 2023-12-31 | CN¥3.15 Billion | CN¥916.74 Million | 0.291x | +18.12% |
| 2022-12-31 | CN¥3.59 Billion | CN¥883.80 Million | 0.246x | -33.34% |
| 2021-12-31 | CN¥3.38 Billion | CN¥1.25 Billion | 0.369x | +9.28% |
| 2020-12-31 | CN¥2.83 Billion | CN¥957.49 Million | 0.338x | +25.70% |
| 2019-12-31 | CN¥2.17 Billion | CN¥583.50 Million | 0.269x | +20.52% |
| 2018-12-31 | CN¥1.72 Billion | CN¥384.08 Million | 0.223x | +2.07% |
| 2017-12-31 | CN¥1.39 Billion | CN¥304.10 Million | 0.219x | +44.85% |
| 2016-12-31 | CN¥1.18 Billion | CN¥178.64 Million | 0.151x | -58.52% |
| 2015-12-31 | CN¥564.06 Million | CN¥205.18 Million | 0.364x | +19.81% |
| 2014-12-31 | CN¥452.42 Million | CN¥137.35 Million | 0.304x | -13.44% |
| 2013-12-31 | CN¥380.12 Million | CN¥133.33 Million | 0.351x | -15.17% |
| 2012-12-31 | CN¥290.84 Million | CN¥120.25 Million | 0.413x | +15.66% |
| 2011-12-31 | CN¥215.57 Million | CN¥77.06 Million | 0.357x | -- |